An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral vector COVID-19 vaccines, such as AstraZeneca and Janssen’s. The findings, published in Vaccine, draw on data from more than 230 million people across 20 global sites. GBS is a rare but serious neurological disorder that […]
The post Study links COVID-19 and some vaccines to increased risk of rare neurological condition appeared first on Pharmafile.
